Editors’ Picks, March 2026: Pediatric Leukemia Development, Low-dose Tamoxifen Use, and More
In March, AACR's journals editors highlighted studies on the development of pediatric leukemia, the use of low-dose tamoxifen, and...
Tag: Breast cancer
In March, AACR's journals editors highlighted studies on the development of pediatric leukemia, the use of low-dose tamoxifen, and...
In February, the editors of AACR's journals highlighted studies on the FDA’s accelerated approval pathway, how metabolism impacts prostate...
Researchers and a patient advocate weighed in on current and emerging treatment options for each stage of triple-negative breast...
In the last quarter of 2025, the FDA announced 20 approvals in oncology, including treatments for lung cancer, multiple...
At the SABCS 2025 View From the Trenches session, experts discussed how new clinical trial results might transform breast...
At SABCS 2025, studies show some patients with early-stage breast cancer can skip steps like SLNB or MRI without...
In clinical trials presented at SABCS, a mobile health tool and acupuncture helped to improve breast cancer survivors' quality...
Amid the debate over menopausal hormone therapy and cancer risk, researchers at SABCS provided some clarity for women with...
Throughout the years, SABCS has shown how tucatinib has progressed into a potential frontline therapy for HER2-positive breast cancer.
In November, the AACR’s journal editors highlighted studies on sucralose limiting immunotherapy, benefits of caloric restriction, and more.